PHS 987 NU Medication Pharmacokinetics Questions

Question 1The information below includes results from a clinical study evaluating
the pharmacokinetics of a test compound (LIU323) after the
administration of an IV bolus dose to a healthy human volunteer.
Dose = 5.5 mg
Cmax =26.0 ng/mL
Elimination half-life = 11.5 hr
Assuming the MEC is 9.0 ug/L, how long would the medication be
effective following administration of a 31.0 mg dose?
Question 2 (1 point)
The table below contains PLASMA concentration-time data for a new medication
(LIU987) following administration of a single IV bolus dose (400 mg). Below the table
is a Ln C vs time plot of the data.
What is the volume of distribution (in Liters)?
Question 3 (1 point)
When 490 mg of a drug is administered as an IV bolus dose, the
plasma concentrations (mg/L) observed over time can be
described by the following equation:
Calculate the volume of distribution (in liters)
Question 4 (1 point)
When 340 mg of a drug is administered as an IV bolus dose, the
plasma concentrations (mg/L) observed over time can be
described by the following equation:
Calculate the clearance. The units should be mL/min for this
calculation.
Question 5 (1 point)
A drug that exhibits one-compartment pharmacokinetics and is
administered by an IV bolus dose. If 70% of the dose remains in
the body after 4hrs, calculate the half-life of the drug (in hours).
Question 6 (1 point)
The information below includes results from a clinical study evaluating
the pharmacokinetics of a test compound (LIU323) after the
administration of an IV bolus dose to a healthy human volunteer.
Dose = 5.5 mg
Cmax =30 ng/mL
Elimination half-life = 5.5 hr
Based on this information, what is the clearance (L/hr) of the LIU 323?
Question 7 (1 point)
A drug that exhibits one-compartment pharmacokinetics and is
administered by an IV bolus dose. if the drug has a t1/2 = 4.5 hr,
what is the percentage (%) of the dose remaining in the body 6.0
hours after dosing?
Question 8 (1 point)
PLASMA concentration-time data are collected for a new medication
(LIU987) following the administration of a single IV bolus dose (200
mg). From the data, the elimination rate constant is estimated to be
0.035 h-1. Based on this information, what is the elimination half-life (in
hr) of LIU987?
Question 9 (1 point)
When 70 mg of a drug is administered as an IV bolus dose, the
plasma concentrations (mg/L) observed over time can be
described by the following equation:
Calculate the AUC(0-infinity). The units should be mg-hr/L.
Question 10 (1 point)
The information below includes results from a clinical study evaluating
the pharmacokinetics of a test compound (LIU323) after the
administration of an IV bolus dose to a healthy human volunteer.
Dose = 3.5 mg
Cmax =28 ng/mL
Elimination half-life = 11.5 hr
If a 31.0 mg IV bolus dose was administered to this subject, calculate
the amount of drug (mg) in the body after 6 hours.
Question 11 (1 point)
When 150 mg of a drug is administered as an IV bolus dose, the
plasma concentrations (mg/L) observed over time can be
described by the following equation:
Calculate the plasma concentration (mg/L) one day after
administration of a 580 mg dose.
Question 12 (1 point)
When 220 mg of a drug is administered as an IV bolus dose, the
plasma concentrations (mg/L) observed over time can be
described by the following equation:
Calculate the elimination half-life (in hours)
Question 13 (1 point)
The information below includes results from a clinical study evaluating
the pharmacokinetics of a test compound (LIU323) after the
administration of an IV bolus dose to a healthy human volunteer.
Dose = 3.5 mg
Cmax =38 ng/mL
Elimination half-life = 7.5 hr
Based on this information, what is the AUC(0-infinity, ug-h/L)) of LIU
323?
Question 14 (1 point)
The information below includes results from a clinical study evaluating
the pharmacokinetics of a test compound (LIU323) after the
administration of an IV bolus dose to a healthy human volunteer.
Dose = 8.5 mg
Cmax =28 ng/mL
Elimination half-life = 10.5 hr
Based on this information, what dose (in mg) would be needed to
produce a Cmax of 75.0 ng/mL in this subject?
PHS 987 Assignment #1: Noncompartment Analysis
The dataset below was obtained from a clinical study investigating the effect of
fluvoxamine (Fluv) on the systemic exposure of tizanidine (TZ). The study (cross-over
design) was conducted on 10 healthy volunteers who received a single oral dose of
tizanidine (4 mg) in the absence and presence of fluvoxamine (100 mg). The table
below presents the mean plasma concentrations of tizanidine vs. time.
Time (hr)
0
0.33
0.67
1
1.5
2
3
4
5
7
9
12
24
TZ Alone
(ng/ml)
0
0.472
1.840
1.906
1.629
1.489
1.140
0.791
0.306
0.088
0.035
ND
ND
TZ+Fluv
(ng/ml)
0
4.787
19.853
23.276
22.314
23.680
23.811
21.887
19.141
14.129
9.527
5.605
0.736
*ND denotes that the drug was not detected in the sample
Analyze the data using noncompartment analysis. Is there a drug:drug interaction
between tizanidine and fluvoxamine? What pharmacokinetic parameters are affected?
Please submit an Excel file showing your analysis.